JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats

Diabetes, Obesity and Metabolism

Volumn 13, Issue 5, 2011, Pages 446-454

  Hata, T ^a   Mera, Y ^a   Tadaki, H ^a   Kuroki, Y ^a   Kawai, T ^a   Ohta, T ^a   Kakutani, M ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Anti obesity drug; Appetite control; Glucagon like peptide 1; Glucose intolerance; Insulin resistance; JTT 130; Microsomal triglyceride transfer protein; Obesity; Peptide yy; Type 2 diabetes

Indexed keywords

ANTIOBESITY AGENT; CARBON DIOXIDE; DIETHYL 2 ({3 DIMETHYLCARBAMOYL 4 [(4' TRIFLUOROMETHYLBIPHENYL 2 CARBONYL) AMINO] PHENYL}ACETYLOXYMETHYL 2PHENYLMALONATE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; PEPTIDE YY; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; FECES; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HISTOLOGY; INSULIN BLOOD LEVEL; LIPID ABSORPTION; LIPID DIET; LIVER; MALE; METABOLIC REGULATION; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; RAT;

EID: 79953046539     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01368.x     Document Type: Article

References (37)

1. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
2. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 2007; 120: S10-S16.
3. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
4. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
5. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
6. Chaput JP, St-Pierre S, Tremblay A. Currently available drugs for the treatment of obesity: sibutramine and orlistat. Mini Rev Med Chem 2007; 7: 3-10.
7. Xie Y, Newberry EP, Young SG et al. Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem 2006; 281: 4075-4086.
8. Mera Y, Odani N, Kawai T et al. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl) amino] phenyl} acetyloxymethyl)-2-phenylmalonate, JTT-130, an intestine-specific inhibitor of microsomal triglyceride transfer protein. J Pharmacol Exp Ther 2011; 336: 321-327.
9. Aggarwal D, West KL, Zern TL et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005; 5: 30.
10. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006; 27: 719-727.
11. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13-23.
12. Hata T, Mera Y, Ishii Y et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther 2011; 336: 850-856.
13. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1187-1209.
14. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
15. Donahey JC, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res 1998; 779: 75-83.
16. Verdich C, Flint A, Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
17. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
18. O'Donovan D, Feinle-Bisset C, Wishart J, Horowitz M. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. Br J Nutr 2003; 90: 849-852.
19. Gallagher D, Belmonte D, Deurenberg P et al. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 1998; 275: E249-E258.
20. Doucet E, Laviolette M, Imbeault P et al. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women. Metabolism 2008; 57: 1458-1464.
21. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007; 292: E1062-E1068.
22. Hwa JJ, Ghibaudi L, Williams P et al. Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 1998; 19: 869-875.
23. Osaka T, Endo M, Yamakawa M, Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 2005; 26: 1623-1631.
24. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 2006; 84: 556-560.
25. Miyazaki, Miwa S, Kodama H et al. Hepatic and intestinal changes in rats treated with T-0126, a microsomal triglyceride transfer protein (MTP) inhibitor. J Toxicol Sci 2007; 32: 161-177.
26. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
27. Wickelgren I. Obesity: how big a problem? Science 1998; 280: 1364-1367.
28. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22(Suppl. 3): C10-C13.
29. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
30. Taylor SI, Barr V, Reitman M. Does leptin contribute to diabetes caused by obesity? Science 1996; 274: 1151-1152.
31. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
32. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361.
33. de Souza CJ, Eckhardt M, Gagen K et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863-1871.
34. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87: 3019-3022.
35. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
36. Sandhu H, Wiesenthal SR, MacDonald PE et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 1999; 48: 1045-1053.
37. Elahi D, Egan JM, Shannon RP et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008; 16: 1501-1509.